Life Sciences

  • May 12, 2026

    Pa. Panel Struggles With Oversight Of $2.2B Opioid Fund

    A Pennsylvania appellate court on Tuesday questioned the system for distributing opioid companies' settlement money, after three counties and the city of Philadelphia said a review board unfairly disapproved their projects after the money was spent.

  • May 12, 2026

    Makary Out As FDA Commissioner, Trump Says

    U.S. Food and Drug Administration Commissioner Marty Makary is departing the agency, President Donald Trump confirmed on Tuesday, bringing to an end a tumultuous, one-year run as one of the nation's top health officials.

  • May 12, 2026

    SPAC, Investors Sue Aesthetics Co. Over Failed $250M Merger

    Viveon Health Acquisition Corp., a SPAC, and several investors have sued Townsgate Village Inc., formerly known as Suneva Medical Inc., in the Delaware Chancery Court, alleging that the aesthetics company strung them along in a failed $250 million special purpose acquisition company merger while secretly looking for another deal.

  • May 12, 2026

    FDA Leaders Outline How AI Is Shaping The Agency's Work

    The U.S. Food and Drug Administration is using generative artificial intelligence to help redact records before public release, summarize documents and evaluate scientific literature, federal officials said in a recent conference.

  • May 12, 2026

    Celgene Gets Final OK For $239M Deal, Atty Fees

    Investors in biopharmaceutical company Celgene Corp. have gotten a final nod for their $239 million deal to end proposed class claims that the company overstated commercial prospects for two of its drugs, and the investors' four-firm legal team will get fees and costs of nearly $57.3 million for their work on the case.

  • May 12, 2026

    Female Medtronic Manager's Firing Driven By Bias, Court Told

    Medtronic fired a longtime manager for disciplining a male subordinate and raising concerns about gender discrimination and retaliation, the worker told a Colorado state court.

  • May 11, 2026

    NJ Justices Back Coverage Exclusion Reservation Of Rights

    The New Jersey Supreme Court on Monday said an insurer doesn't waive its right to rely on a policy exclusion after initially defending a claim, backing Berkley Insurance Co. in a coverage dispute stemming from self-dealing suits against a pharmaceutical company and its chairman.

  • May 11, 2026

    Wash. Says Novartis Isn't Harmed By 340B Drug Pricing Law

    Washington is objecting to Novartis' attempt to block a state law that expands the discounts the drugmaker must provide under the federal 340B Drug Pricing Program, telling a federal court that worry about losing money doesn't constitute irreparable harm.

  • May 11, 2026

    Nestlé Sues To Unmask Amazon Sellers Of 'Stolen' Vitamins

    Nestlé Health Science U.S. filed a lawsuit in Washington state Friday in an effort to unmask "suspected bad actors" whom it accuses of illegally intercepting high volumes of nutritional supplements and funneling them to resellers on Amazon.com.

  • May 11, 2026

    Mead Johnson Heads To Trial In Ill. Baby Formula MDL

    An Illinois federal judge handling multidistrict litigation over baby formula that allegedly caused a serious abdominal condition in premature infants rejected Mead Johnson & Co. LLC's summary judgment bid in the fourth lawsuit parties had selected as an MDL tester case, teeing up the litigation's first trial.

  • May 11, 2026

    Beauty Tech Co. Execs Beat Investor Suit For Good

    A California federal judge Monday tossed a proposed class action accusing beauty technology firm Cutera and its executives of misleading investors about its acne treatment launch and financial results, finding the legal claims against the company were abandoned and discharged under its Chapter 11 plan.

  • May 11, 2026

    Pharma CEO's Role In Ex-Exec's Contract Permits Deposition

    North Carolina's business court has refused to shield the CEO of biopharmaceutical firm United Therapeutics Corp. from being deposed in a trade secrets lawsuit against a former executive and his new employer, finding it reasonable to believe she was an "ultimate decision-maker."

  • May 11, 2026

    Amgen Late To Raise Double-Taxation Claim, Tax Court Told

    Biotechnology giant Amgen is making a "futile" attempt to raise a purported double-taxation issue for tax years 2016 through 2018 in a pair of transfer pricing cases before the U.S. Tax Court, the federal government said, arguing the disputed years fall outside the court's jurisdiction.

  • May 11, 2026

    Trading Scheme Is A 'Wake-Up Call' For BigLaw Compliance

    The breadth of a decade-long insider trading scheme prosecutors say was fueled by stolen BigLaw merger information should jolt firms to reexamine their practices to close gaps in internal security, experts told Law360, even if totally eliminating bad actors is nearly impossible.

  • May 11, 2026

    Justices Extend Stay On 5th Circ. Mifepristone Decision

    The U.S. Supreme Court on Monday extended a stay that preserved, for now, telehealth access to the abortion medication mifepristone.

  • May 11, 2026

    Fed. Circ. Backs Atty Fee Ruling In Bone Fusion Patent Row

    The Federal Circuit on Monday backed a lower court that awarded $52,573 in attorney fees for Nextremity Solutions Inc.'s defense against a bone fusion patent suit and shot down Nextremity's bid for $343,660 in fees incurred at the Patent Trial and Appeal Board.

  • May 11, 2026

    Plaintiffs' Attys Sanctioned In Tylenol MDL, Sparking Appeal

    A New York federal court sanctioned a plaintiffs' firm and its co-founder in federal multidistrict litigation by families alleging that prenatal exposure to acetaminophen can cause autism, saying they improperly shared confidential information from the case in related state court actions.

  • May 08, 2026

    Ex-FDA Chief Says J&J Atty 'Spinning' Asbestos Definition

    A former U.S. Food and Drug Administration commissioner told an attorney for Johnson & Johnson she was "spinning" the definition of asbestos in an attempt to confuse a jury in a bellwether trial over claims the company's talc products caused three women's deaths from ovarian cancer.

  • May 08, 2026

    FTC's Gender-Care Probe Likely Retaliatory, Judge Says

    The Endocrine Society has convinced a D.C. federal judge that the Federal Trade Commission's motivation for targeting it with a subpoena was likely retaliation for the guidelines the nonprofit produced regarding gender-affirming care.

  • May 08, 2026

    10x, Curio Settle Genomics Patent Suit Before Trial

    10x Genomics on Friday said it has agreed to end its suit accusing Curio Bioscience of infringing a series of Prognosys Biosciences genomics technology patents that 10x Genomics is licensed to use.

  • May 08, 2026

    Sports Tech Co. Says Judge Made Own Patent Eligibility Case

    Finnish sports tech company Polar Electro has asked the U.S. Supreme Court to revive its infringement case against a rival over a heart monitoring patent, saying a district judge made up his own case for patent eligibility when he ruled the patent was invalid.

  • May 08, 2026

    10x, Harvard Sue Sequencing Co. Over Biology Patents

    10x Genomics Inc. and Harvard have sued Element Biosciences Inc. in Delaware federal court, accusing the San Diego sequencing company of infringing four Harvard-owned patents through Element's AVITI24 platform and related Teton chemistry.

  • May 08, 2026

    Ex-Wachtell Lipton Atty Tied To Stolen BigLaw Info Trades

    A former Wachtell Lipton Rosen & Katz attorney who later worked for investment bank LionTree LLC is an unindicted co-conspirator in a sweeping alleged insider trading scheme that involved stolen information from several prominent law firms, according to a review of publicly available information.

  • May 08, 2026

    Covington, Cooley Lead Drugmaker Odyssey's $279M IPO

    Venture-backed biotechnology firm Odyssey Therapeutics began trading publicly Friday after raising $279 million in its initial public offering, making it the latest biotech to hit the public markets over the last few weeks.

  • May 08, 2026

    Squires Says Yes To 7 Patent Petitions, No To A Dozen More

    U.S. Patent and Trademark Office Director John Squires granted seven petitions for patent review under the America Invents Act and denied 12 other petitions, including a host of challenges by Cisco Systems and Samsung Electronics.

Expert Analysis

  • Opinion

    Supreme Court Term Limits Would Carry Hidden Risk

    Author Photo

    While proposals for limiting the terms of U.S. Supreme Court justices are popular, a steady stream of relatively young, highly marketable ex-justices with unique knowledge and influence entering the marketplace of law and politics could create new problems, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware.

  • Next Steps For Orgs. Amid Updated OpenAI Usage Policies

    Author Photo

    OpenAI's updates to its usage policies, clarifying that its tools are not substitutes for professional medical, legal or other regulated advice, sends a clear signal that organizations should mirror this clarity in their governance policies to mitigate compliance and liability exposure, say attorneys at Baker Donelson.

  • Series

    Knitting Makes Me A Better Lawyer

    Author Photo

    Stretching my skills as a knitter makes me a better antitrust attorney by challenging me to recalibrate after wrong turns, not rush outcomes, and trust that I can teach myself the skills to tackle new and difficult projects — even when I don’t have a pattern to work from, says Kara Kuritz at V&E.

  • How 11th Circ.'s Qui Tam Review Could Affect FCA Litigation

    Author Photo

    On Dec. 12, the Eleventh Circuit will hear arguments in U.S. ex rel. Zafirov v. Florida Medical Associates, setting the stage for a decision that could drastically reduce enforcement under the False Claims Act, and presenting an opportunity to seek U.S. Supreme Court review of the act's whistleblower provisions, say attorneys at Epstein Becker.

  • Series

    The Biz Court Digest: Welcome To Miami

    Author Photo

    After nearly 20 years in operation, the Miami Complex Business Litigation Division is a pioneer upon which other jurisdictions in the state have been modeled, adopting many innovations to keep its cases running more efficiently and staffing experienced judges who are accustomed to hearing business disputes, say attorneys at King & Spalding.

  • Identifying And Resolving Conflicts Among Class Members

    Author Photo

    As the Fifth Circuit's recent decision in Nova Scotia Health Employees' Pension Plan v. McDermott International illustrates, intraclass conflicts can determine the fate of a class action — and such conflicts can be surprisingly difficult to identify, says Andrew Faisman, a clerk at the U.S. District Court for the Southern District of New York.

  • Adapting To A Plaintiff-Side Mindset For Patent Monetization

    Author Photo

    A recent decrease in risk for patent owners at the U.S. Patent and Trademark Office, combined with increased corporate interest in monetizing patent assets, creates an attractive case for evaluating patents from a plaintiff-side mindset, but in-house counsel transitioning from a defense-side mindset to a plaintiff-side mindset should study certain considerations, says Kate Tellez at Steptoe.

  • AI Evidence Rule Tweaks Encourage Judicial Guardrails

    Author Photo

    Recent additions to a committee note on proposed Rule of Evidence 707 — governing evidence generated by artificial intelligence — seek to mitigate potential dangers that may arise once machine outputs are introduced at trial, encouraging judges to perform critical gatekeeping functions, say attorneys at Lankler Siffert & Wohl.

  • Series

    The Law Firm Merger Diaries: Getting The Message Across

    Author Photo

    Communications and brand strategy during a law firm merger represent a crucial thread that runs through every stage of a combination and should include clear messaging, leverage modern marketing tools and embrace the chance to evolve, says Ashley Horne at Womble Bond.

  • Opinion

    Horizontal Stare Decisis Should Not Be Casually Discarded

    Author Photo

    Eliminating the so-called law of the circuit doctrine — as recently proposed by a Fifth Circuit judge, echoing Justice Neil Gorsuch’s concurrence in Loper Bright — would undermine public confidence in the judiciary’s independence and create costly uncertainty for litigants, says Lawrence Bluestone at Genova Burns.

  • 10 Commandments For Agentic AI Tools In The Legal Industry

    Author Photo

    Though agentic artificial intelligence has demonstrated significant promise for optimizing legal work, it presents numerous risks, so specific ethical obligations should be built into the knowledge base of every agentic AI tool used in the legal industry, says Steven Cordero at Akerman LLP.

  • Fed. Circ. In Oct.: Spotlight On Wording Beyond Patent Claims

    Author Photo

    The Federal Circuit's recent decision in Barrette Outdoor Living v. Fortress Iron provides useful guidance on how patent prosecutors should avoid language that triggers specification disclaimer and prosecution disclaimer, doctrines that may be used to narrow the scope of patent infringement claims, say attorneys at Knobbe Martens.

  • New Drug Ad Regs Could Lead To A Less Informed Public

    Author Photo

    A federal push to mandate full safety warnings in pharmaceutical advertising could make drug ads less appealing for companies to air, which in turn could negatively affect consumers' health decisions by removing an accessible information source, say Punam Keller at Dartmouth College and Ceren Canal Aruoba at Berkeley Research Group.

  • Series

    Preaching Makes Me A Better Lawyer

    Author Photo

    Becoming a Gospel preacher has enhanced my success as a trial lawyer by teaching me the importance of credibility, relatability, persuasiveness and thorough preparation for my congregants, the same skills needed with judges and juries in the courtroom, says Reginald Harris at Stinson.

  • A Look At Middlemen Fees In 340B Drug Discount Program

    Author Photo

    A U.S. Senate committee's recent hearing on the Section 340B drug discount program, along with statistical analysis of payment amounts, contribute to a growing consensus that middlemen fees are too high, say William Sarraille at the University of Maryland, and Shanyue Zeng and Rory Martin at IQVIA.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.